SEC Form 4 · accession 0000899243-16-025724
Larimar Therapeutics, Inc. · LRMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patricia L Allen
Officer — Chief Financial Officer
Period of report
Jul 25, 2016
Accepted (ET)
Jul 26, 2016 · 5:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001374690
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 25, 2016 | P | 7,800 | $3.081 | A | 11,593 | D | |
| Common StockF3,F2 | Jul 26, 2016 | P | 8,200 | $3.15 | A | 19,793 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at a price ranging from $3.05 to $3.11, inclusive. The reporting person undertakes to provide to Zafgen, Inc., any security holder of Zafgen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- F2The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at a price ranging from $3.10 to $3.16, inclusive. The reporting person undertakes to provide to Zafgen, Inc., any security holder of Zafgen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- F3Includes 2,500 shares acquired under Zafgen, Inc.'s 2014 Employee Stock Purchase Plan (the "Plan") on July 1, 2016; 200 shares acquired under the Plan on January 1, 2016; 585 shares acquired under the Plan on July 1, 2015; and 508 shares acquired under the Plan on January 1, 2015.